Search Results - "ZIMMERMANN, Annamaria H"

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer by PAZ-ARES, Luis G, DE MARINIS, Filippo, CORRAL, Jesús, MELEMED, Symantha, JOHN, William, CHOUAKI, Nadia, ZIMMERMANN, Annamaria H, VISSEREN-GRUL, Carla, GRIDELLI, Cesare, DEDIU, Mircea, THOMAS, Michael, PUJOL, Jean-Louis, BIDOLI, Paolo, MOLINIER, Olivier, TARINI PRASAD SAHOO, LAACK, Eckart, RECK, Martin

“…In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62;…”
Get full text

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial by Paz-Ares, Luis, Dr, de Marinis, Filippo, MD, Dediu, Mircea, MD, Thomas, Michael, Prof, Pujol, Jean-Louis, Prof, Bidoli, Paolo, MD, Molinier, Olivier, MD, Sahoo, Tarini Prasad, MD, Laack, Eckart, Prof, Reck, Martin, MD, Corral, Jesús, MD, Melemed, Symantha, PhD, John, William, MD, Chouaki, Nadia, MD, Zimmermann, Annamaria H, MS, Visseren-Grul, Carla, MD, Gridelli, Cesare, MD

“…Summary Background Patients with advanced non-squamous non-small-cell lung cancer (NSCLC) benefit from pemetrexed maintenance therapy after induction therapy…”
Get full text

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer by Nakagawa, Kazuhiko, Nadal, Ernest, Garon, Edward B, Nishio, Makoto, Seto, Takashi, Yamamoto, Nobuyuki, Park, Keunchil, Shih, Jin-Yuan, Paz-Ares, Luis, Frimodt-Moller, Bente, Zimmermann, Annamaria H, Wijayawardana, Sameera, Visseren-Grul, Carla, Reck, Martin

“…In EGFR-mutated metastatic non-small cell lung cancer (NSCLC), outcomes from EGFR tyrosine kinase inhibitors have differed historically by mutation type…”
Get full text

Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy by Wit, Ronald, Powles, Thomas, Castellano, Daniel, Necchi, Andrea, Lee, Jae‐Lyun, Heijden, Michiel S., Matsubara, Nobuaki, Bamias, Aristotelis, Fléchon, Aude, Sternberg, Cora N., Drakaki, Alexandra, Yu, Evan Y., Zimmermann, Annamaria H., Long, Amanda, Walgren, Richard A., Gao, Ling, Bell‐McGuinn, Katherine M., Petrylak, Daniel P.

“…Aims Patients with advanced urothelial carcinoma (UC) who progress after platinum‐based chemotherapy have a poor prognosis, and there is a medical need to…”
Get full text

PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer by Reck, Martin, Paz-Ares, Luis G, de Marinis, Filippo, Molinier, Olivier, Sahoo, Tarini Prasad, Laack, Eckart, John, William, Zimmermann, Annamaria H, Visseren-Grul, Carla, Gridelli, Cesare

“…The PARAMOUNT phase III trial demonstrated that pemetrexed continuation maintenance significantly reduced the risk of disease progression (hazard ratio = 0.62)…”
Get more information

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy by Garon, Edward B, Scagliotti, Giorgio Vittorio, Gautschi, Oliver, Reck, Martin, Thomas, Michael, Iglesias Docampo, Lara, Kalofonos, Haralabos, Kim, Joo-Hang, Gans, Steven, Brustugun, Odd Terje, Orlov, Sergey V, Cuyun Carter, Gebra, Zimmermann, Annamaria H, Oton, Ana B, Alexandris, Ekaterine, Lee, Pablo, Wolff, Katharina, Stefaniak, Victoria Jennifer, Socinski, Mark A, Pérol, Maurice

“…IntroductionNon-small-cell lung cancer (NSCLC) is a heterogeneous disease. Front-line therapy may affect responses to subsequent treatment regimens, thus…”
Get full text

RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor ( EGFR )-mutated metastatic non-small cell lung cancer (NSCLC) by Nishio, Makoto, Nishio, Kazuto, Reck, Martin, Garon, Edward B., Imamura, Fumio, Kawaguchi, Tomoya, Yamaguchi, Hiroyuki, Ikeda, Satoshi, Hirano, Katsuya, Visseren-Grul, Carla M, Widau, Ryan C, Zimmermann, Annamaria H., Homma, Gosuke, Enatsu, Sotaro, Nakagawa, Kazuhiko

“…Abstract only 9564 Background: The phase III randomized part of the RELAY study (Part B; RELAY; NCT02411448) showed a significant improvement in…”
Get full text

Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC) by Martin, Miguel, Hegg, Roberto, Kim, Sung-Bae, Schenker, Michael, Grecea, Daniela, García-Sáenz, José A., Papazisis, Konstantinos, Ouyang, Quchang, Lacko, Aleksandra, Oksuzoglu, Berna, Reeves, James Andrew, Okera, Meena, Testa, Laura, Shimizu, Chikako, Wei, Ran, Forrester, Tammy D, Munoz, Maria, Zimmermann, Annamaria H., Headley, Desiree, Johnston, Stephen R. D.

“…Abstract only 517 Background: monarchE, a phase 3, open-label, randomized study evaluating abemaciclib combined with adjuvant endocrine therapy (ET) compared…”
Get full text

RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC) by Nakagawa, Kazuhiko, Garon, Edward B., Seto, Takashi, Nishio, Makoto, Ponce Aix, Santiago, Chiu, Chao-Hua, Park, Keunchil, Novello, Silvia, Nadal, Ernest, Imamura, Fumio, Yoh, Kiyotaka, Shih, Jin-Yuan, Au, Kwok Hung, Moro-Sibilot, Denis, Enatsu, Sotaro, Zimmermann, Annamaria H., Frimodt-Moller, Bente, Visseren Grul, Carla M., Reck, Martin

“…Abstract only 9000 Background: Dual blockade of EGFR and VEGFR pathways in EGFRm NSCLC augments anti-tumor efficacy versus (v) EGFR inhibition alone. RELAY…”
Get full text

Ramucirumab (RAM) exposure-response (ER) relationship in RANGE: A randomized phase III trial of RAM plus docetaxel (DOC) versus placebo (P) plus DOC in advanced platinum-refractory urothelial carcinoma (UC) patients (pts) by De Wit, Ronald, Powles, Thomas, Castellano, Daniel E., Necchi, Andrea, Lee, Jae-Lyun, Van Der Heijden, Michiel Simon, Matsubara, Nobuaki, Bamias, Aristotelis, Flechon, Aude, Sternberg, Cora N., Drakaki, Alexandra, Yu, Evan Y., Hamid, Oday, Zimmermann, Annamaria H., Gao, Ling, Long, Amanda, Walgren, Richard A., Bell-McGuinn, Katherine M, Petrylak, Daniel Peter

“…Abstract only 353 Background: Recent RANGE results showed significant improvement in PFS, a non-significant positive trend in OS, increased ORR and acceptable…”
Get full text